SCHEMBL5475202

SCHEMBL5475202

FC(F)(F)c1ccccc1CN1CCC(OCc2c[nH]cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
ATM Q13315 2/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 2/20 0.44
CHRM1 P11229 3/20 0.43
TDP1 Q9NUW8 2/20 0.42
RECQL P46063 1/20 0.42
KCNH2 Q12809 1/20 0.42
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
SCD O00767 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606815 0.84 CARM1 (0.52) CARM1PRMT6KDM4EALDH1A1ATM
SCHEMBL605906 0.84 MPO (0.47) CARM1PRMT6KDM4EALDH1A1KMT2A
SCHEMBL604129 0.84 ACHE (0.50) CARM1PRMT6ALDH1A1KMT2ACHRM1
SCHEMBL603435 0.82 ACHE (0.51) KMT2ADRD4DRD3SIGMAR1MEN1
SCHEMBL604939 0.82 CHRM3 (0.52) CARM1PRMT6POLBKMT2ACHRM1
SCHEMBL605044 0.81 SMN1; SMN2 (0.42) CARM1PRMT6CHRM1DRD4DRD3
SCHEMBL604926 0.81 CHRM1 (0.43) CARM1PRMT6CHRM1DRD4SIGMAR1
SCHEMBL605452 0.81 JAK2 (0.46) CARM1PRMT6DRD4DRD3TMEM97
SCHEMBL606943 0.80 SIGMAR1 (0.45) CARM1PRMT6SCN5ASCN9ADRD4
SCHEMBL605907 0.80 SIGMAR1 (0.41) CARM1PRMT6KDM4EALDH1A1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 US claimed
EP-1651634-A1 IMIDAZOL DERIVATIVES OF PIPERIDINE AS HISTAMINE ANTAGONISTS AstraZeneca AB (SE) 2006-05-03 EP claimed
WO-2005014579-A1 IMIDAZOL DERIVATIVES OF PIPERDINE AS HISTAMINE ANTAGONISTS ASTRAZENECA AB (SE) 2005-02-17 WO claimed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 US disclosed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 US disclosed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists HRH2, HRH1, HRH4 CARM1 400/4885PRMT6 644/4885KDM4E 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.